BOLD — Boundless Bio Inc.

Status note KOMODO-1 first-in-human trial (Part 2 dose expansion planned BBI-940 single agent or with fulvestrant). Terminated: the 10-Q states that preliminary exposure data from early KOMODO-1 dose-escalation cohorts, showing human oral bioavailability significantly lower than preclinical predictions, did not support continued clinical development. Company note: on June 22, 2026 Boundless Bio entered an Agreement and Plan of Merger with Serapha Bio (advancing SERP-01, an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency), expected to close Q4 2026; future operations highly dependent on merger completion.

Status note Phase 1/2 POTENTIATE trial in oncogene-amplified cancers. May 2025: discontinued monotherapy arm and combination arms with third-party targeted therapies based on initial trial data. January 2026: ceased enrollment of the POTENTIATE trial entirely following strategic portfolio review (market considerations, clinical data, prioritization of BBI-940).

Status note Ribonucleotide reductase (RNR) inhibitor designed to target ecDNA assembly and repair. Filing states a strategic decision not to proceed with evaluation in the planned first-in-human STARMAP Phase 1/2 trial; STARMAP winddown completed in 2025.